Label change impact assessment that finds every live piece a new label makes outdated — and proves the withdrawals are gone
Every live piece built on old label text found and fixed or withdrawn.
See one case, screen by screen ↓It is the work of finding every live promotional piece that relies on label text a new label changes, and deciding for each whether to withdraw it, revise it or update its safety text. Label Change Impact Assessment does the finding with six agents that compare the labels, map the changes to claims, read every channel and propose an action with both citations; the regulatory advertising lead decides and signs.
How to choose AI solutions for life sciences →
Updated
When FDA approves a labeling supplement, the approval letter asks for every promotional piece to be revised to match the new label, with prominent disclosure of any new safety information, and for a statement of intent to comply within 7 days. A brand runs hundreds of live pieces: rep detail aids on iPads, rep-triggered emails, HCP and patient websites, paid search and display, social, print, speaker decks and HCP email. The regulatory advertising lead and content operations search the content system by keyword, email the agencies and the field, and hope nothing was missed.
Keyword search misses the pieces that matter most. A detail aid says “No lab tests needed between visits” where the claims library says “No routine laboratory monitoring is required”; a display banner still quotes the old 3%; a detail aid cites “Source: USPI Table 5”. Most of the inventory is not impacted, but nobody can prove it without opening each piece. And a withdrawal closed in one system lives on in another — a CLM device that has not synced, a CRM template, printed stock in a rep's car.
Estimated split for one label change on a brand with about 300 live pieces, by hand and with the solution.
Six specialist agents compare the labels, read every channel and follow each piece through; the regulatory advertising lead decides.
Northwind Bio's Veltrimab, an IL-23 biologic for plaque psoriasis and psoriatic arthritis, has a new US Prescribing Information: Rev. 10/2026, approved October 2, 2026. It adds a hepatotoxicity warning. It is October 7, day 5. Here is what happens next, screen by screen, in the working solution.
Dana opens on the impact map: six label changes on the left, what to do in the middle, the nine channels where pieces are live on the right. 312 live pieces were read, 225 cleared by the shared safety module and 87 impacted — 9 withdraw now, 46 revise, 32 safety text. The new liver warning, §5.4, is the critical one, and 4 withdrawals are waiting for her, due Oct 9.
“Any “no lab monitoring” claim is now contradicted by safety information, and safety text built into a piece must carry the new warning with prominent disclosure.”
Clicking Withdraw now lights its bands and lists the pieces: 2 rep detail aids, 2 rep emails, 2 paid search and display, 1 HCP web page, 1 social post and 1 print piece. Seven come from the liver warning. Two use the old 3% injection-site rate to play down risk; the label now says 5%.
“A claim the new label contradicts, or an old number used to play down risk. Out of use within the withdraw-now clock.”
The cleared pieces join the map as a green flow: 139 carry the shared safety module and 86 link to the shared safety page. The module was updated once, to v10/2026 on Oct 3, and none of these pieces quotes changed text. Nobody had to open them.
“Each carries the module in its own layout: the web safety footer, the detail aid safety slide or the email safety block.”
Dana does not take the clearance on trust. The spot-check re-reads 12 cleared pieces from 7 systems, text and images, and checks each for module v10/2026. All 12 are confirmed, and the result goes on the audit trail.
“12 of 12 confirmed. Each carries or links to safety module v10/2026 and quotes none of the changed text.”
On Label changes, “Find every piece” runs the sweep in view. The label differ compares Rev. 03/2026 with Rev. 10/2026 section by section and rates each change: 1 critical warning, 2 high, 2 medium, 1 low. The claim mapper finds 9 claims-library entries that rely on changed text and retires CL-VEL-031. The searcher reads 312 pieces four ways, and the classifier proposes an action for each.
Task writer: “20 proposals waiting for Dana Okafor — nothing opens until you decide.”
The pieces list shows each impacted piece with its channel, the label section it relies on, the proposed action, how it was found — exact text, number, reference or meaning — its status, due date and owner. “Your first 16 weeks”, “Simple to start”, “Starting and staying on Veltrimab” and “Injection-day video post” wait for her, due Oct 9.
The detail aid opens on the flagged slide, with both passages side by side: the line in the piece and the new §5.4 text, “Evaluate liver enzymes and bilirubin at baseline, at Weeks 4, 8 and 12”. Found by meaning, confidence 97. It is live on 412 rep iPads, linked to the CRM template “Starting your patients” (sent 1,284 times in 30 days), and 4,180 printed copies are in stock, about 2,020 with reps.
“Says no lab monitoring is needed. The new label requires liver tests at baseline and at Weeks 4, 8 and 12 — the claim is contradicted by new safety information, so the piece cannot stay in use.”
The agents propose Withdraw now; the other choices are Revise, Safety text only and Not impacted, which needs a reason and Legal's second approval. Dana chooses Withdraw now and signs with her password and the meaning of her signature.
“I approve withdrawing “Starting and staying on Veltrimab” from every channel” — recorded with her name, the time and the cited passages.
Only after the signature do tasks open: the content system expires US-VEL-26-0412 v3 so it cannot be used or ordered, the rep iPads remove it at the next sync, the CRM template is deactivated, the field recalls printed copies and confirms destruction, and the brand decides whether a revised version is needed. Each task has its owner — Sam Patel, Omar Haddad, Priya Raman.
“Withdrawal under way — tasks open in every channel.”
On the fix tracker the intent to comply is drafted and due Oct 9: 9 pieces withdrawn from use by Oct 9, safety information updated on 257 by Oct 16, and 46 revised and resubmitted on Form FDA 2253 by Nov 1. Every count links to its pieces. Dana signs it and sends it to Regulatory Affairs, who file it with FDA.
“All promotional materials that include representations about VELTRIMAB will be revised to be consistent with the labeling approved on October 2, 2026, with prominent disclosure of the new Hepatotoxicity warning (5.4).”
The same label change, seen by the five people who carry it — what it looked like before, and what it looks like now.
Six specialist agents compare the labels, read every channel and follow each piece through; the regulatory advertising lead decides.
Compares the new label with the one in use, section by section, and explains each change in plain words with its type and its severity for promotion — critical when new safety information can contradict a claim.
Links each change to the claims-library entries and safety blocks that rely on the old text, and proposes retiring a claim, a new version or a new claim.
Reads every live approved piece in every channel four ways — exact claim text, changed numbers, old table or section references and meaning — including text inside images and charts, and notes whether a piece uses the shared safety module or built-in safety text.
Proposes withdraw now, revise, safety text update or no change for each piece, with both citations, the reason in one or two plain sentences and a confidence.
Turns each signed decision into tasks in every system where the piece lives, writes revision briefs with the exact new label wording, and drafts the statement of intent to comply from the impact list.
Reads back from each system — document state, device sync counts, page and placement status, warehouse stock and field confirmations — and re-opens anything that reappears.
Decides and signs. The agents propose; a named person decides.
Ask in plain words, or say what to change. Every answer cites the label passage or the piece behind it.
Which pieces still promise no lab monitoring?
7 pieces say or imply that no lab monitoring is needed — the new warning 5.4 requires liver tests at baseline and Weeks 4, 8 and 12. Three are retired, “Veltrimab at a glance” is pulled and confirming, and 3 still need your decision before Oct 9. Three use their own wording (“no lab tests needed between visits”) and were found by meaning.
Draft the statement of intent to comply
Drafted from the impact list for 21 CFR 601.12(a)(4), due Oct 9: 9 withdrawn by Oct 9, safety information updated on 257 by Oct 16, 46 revised on Form 2253 by Nov 1. It commits to prominent disclosure of the new liver warning. I opened it for your signature.
Add a rule: pause paid media within 24 hours of a safety change
Done. When a label adds a warning, paid search and display placements that carry an affected claim are paused within 24 hours, before your decision on each piece. Today it would have paused 1 placement still waiting — the display banners were already pulled on Oct 3. The rule is in Settings and in the audit trail.
What is still live on the old label?
62 pieces — 10 rep detail aids, 9 HCP web pages, 9 print, 7 rep emails, 7 patient web pages and 6 paid search and display among them. 4 are withdraw-now pieces waiting for you; the rest are revisions with agencies or in MLR, which stay live until the revised version is approved. Printed copies: 61 of 96 reps have confirmed their recall.
13 screens from the working solution, on its sample data. Pick one to see it large.
The clocks, decision makers and matching rules every label change runs on are settings, versioned and recorded in the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Withdraw-now pieces out of use | 5 business days | 5 · 3 · 2 business days |
| Built-in safety text updated | 10 business days | 10 · 5 business days |
| Revisions republished | 30 days | 30 · 45 days |
| Statement of intent to comply | Draft on day 1, remind on day 5 | Draft on day 1, remind on day 5 · Draft on day 1, remind on day 3 |
| Withdraw, revise or update — signs every decision | Dana Okafor | Dana Okafor · Lena Ortiz |
| Second approval for “Not impacted” on a safety change | Lena Ortiz, Legal | Lena Ortiz, Legal · Dr. Maya Chen, Medical |
| Revised pieces reviewed by | Standard MLR team | Standard MLR team · Fast track, one reviewer |
| Matching | Meaning, changed numbers and table references, and drafts still in MLR — all on | Each on or off |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample label change · “estimated” = our estimate · “typical” = published figures (FDA supplement approval letters under 21 CFR 314.70(a)(4) and 601.12(a)(4) — statement of intent to comply within 7 days). Northwind Bio, Veltrimab, Corventa, Talmirex and the people named on this page are fictional — characters and sample data in the working solution.
It is the work of finding every live promotional piece that relies on label text a new label changes, and deciding for each whether to withdraw it, revise it or update its safety text. Label Change Impact Assessment does the finding with six agents that compare the labels, map the changes to claims, read every channel and propose an action with both citations; the regulatory advertising lead decides and signs.
The inventory searcher reads every piece four ways: exact claim text, changed numbers, old table or section references, and meaning — including text inside images and charts. On the sample label change, 13 of the 87 impacted pieces were found by meaning alone, such as “No lab tests needed between visits” for a no-monitoring claim.
No. Pieces that carry or link to the shared safety module and quote none of the changed text are cleared automatically and shown on the map with the reason — 225 of 312 in the sample. You can spot-check a sample of them; the result is recorded in the audit trail.
Yes. The task writer drafts it from the impact list on day 1: how many pieces will be withdrawn, have safety information updated or be revised and resubmitted on Form FDA 2253, and by when. The regulatory advertising lead signs it and sends it to Regulatory Affairs, who file it with FDA.
The completion tracker reads back from each system the piece lived in — content system state, rep iPad sync counts, CRM templates, web pages, media placements, warehouse stock and field recall by territory. A withdrawal is confirmed only when every channel shows it gone, and the task is re-opened if the piece reappears.
Yes. The agents only propose. The regulatory advertising lead decides each piece and signs with her name, the meaning and the time; “Not impacted” on a safety change needs Legal's second approval; and no task opens before a signed decision.
Yes. The withdraw-now, safety text and revision clocks, the intent-to-comply reminder, who decides, who gives the second approval, the MLR route, the rules, the sources the agents read and the matching are all settings, versioned and on the audit trail.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your withdrawal procedure, your labels, claims library and a list of the systems your pieces live in — and it goes live once every quality gate has passed. We will walk you through it on one of your own past label changes first.
The quarterly risk narrative drafted in minutes, every figure from a live query
1-min demoSales Playbook AutomationThe right playbook for every market and product, built 70% faster.
1-min demoChargeback ProcessingEvery chargeback claim read first, each verdict with its rule and evidence
1-min demoWe'll run Label Change Impact Assessment on one of your past label changes and your live content inventory.